Elevance Health posted $418 million in profit for the fourth quarter of 2024, a figure that surpassed Wall Street's expectations despite decreasing 51% year-over-year. | Elevance Health posted $418 million in profit for the fourth quarter of 2024,

U.S. stocks are drifting near a record as Wall Street’s recent rally loses some momentum. The S&P 500 slipped 0.1% in early trading Thursday, a day after after pulling to the edge of its all-time high set in early December.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $492.5, with a high estimate of $512.00 and a low estimate of $478.00. A decline of 6.69% from the prior average price target is evident in the current average.

StockNews.com cut shares of Elevance Health (NYSE:ELV – Free Report) from a buy rating to a hold rating in a research note issued to investors on Monday morning. Several other research firms also recently weighed in on ELV.

Financial writer recommends buying Elevance Health stock despite recent drop, citing strong industry trends and potential for significant upside.

Elevance Health (ELV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Scott Fidel from

After a dip in the wake of the release of UnitedHealth Group's Q4 2024 earnings figures, shares in the company and other managed care insurers have largely bounced back.

The Indianapolis-based company said it had net income of $1.81 per share. Earnings, adjusted for one-time gains and costs, came to $3.84 per share. The results beat Wall Street expectations. The average estimate of 17 analysts surveyed by Zacks Investment Research was for earnings of $3.80 per share.

Health-care companies rose sharply amid strong earnings.

Wall Street analysts forecast that Elevance Health (ELV) will report quarterly earnings of $3.82 per share in its upcoming release, pointing to a year-over-year decline of 32%. It is anticipated ...

Flagship Harbor Advisors LLC increased its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 29.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission.

We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click here to read more.